Baidu
map

Hepatology:预测肝硬化患者发生肝性脑病的因素!

2017-11-02 MedSci MedSci原创

超过40%的肝硬化患者会发展为肝性脑病(HE)。研究表明,HE与患者的生存下降、跌倒、机动车辆事故以及住院频率增加密切相关。近期,一项发表在杂志Hepatology上的研究旨在开发一种能够对发展为HE患者的风险分层的工具。此项研究为基于人群队列的所有肝硬化患者,包括来自密歇根州、印第安纳州和俄亥俄州的退伍军人管理局(1/1 / 2005-12 / 31/10),所有受试人群在基线时均无HE(N =

超过40%的肝硬化患者会发展为肝性脑病(HE)。研究表明,HE与患者的生存下降、跌倒、机动车辆事故以及住院频率增加密切相关。


近期,一项发表在杂志Hepatology上的研究旨在开发一种能够对发展为HE患者的风险分层的工具。

此项研究为基于人群队列的所有肝硬化患者,包括来自密歇根州、印第安纳州和俄亥俄州的退伍军人管理局(1/1 / 2005-12 / 31/10),所有受试人群在基线时均无HE(N = 1,979)。主要研究结果是HE的发展。使用基线和纵向数据(每年更新的参数)构建风险评分,并使用自举验证。
此项研究结果显示:人群队列的平均年龄58.0±8.3岁,丙型肝炎占36%,腹水占17%。在基线时使用阿片类药物、苯二氮卓类药物、他汀类药物和非选择性β-受体阻滞剂分别占24%、13%、17%和12%。

总体而言,5年内共有863(43.7%)人发展为HE。在多变量模型中,HE的危险因素(HR,95%CI)包括高胆红素(1.07,1.05〜1.09)和非选择性β-阻滞剂的使用(1.34,1.09-1.64),而高白蛋白(0.54,0.48-0.59)和他汀类药物使用(0.80,0.65-0.98)具有保护作用。

其他临床因素,包括阿片类和苯二氮卓类药物的使用并不具有预测性。在基线和纵向模型中使用4个重要变量的AUROC分别为0.68(0.66-0.70)和0.73(0.71-0.75)。纵向模型的得分≤0则1年的HE风险为6%,而得分> 20则1年的HE风险为38%。

此项研究结果表明:肝硬化的患者可以通过简单的风险评分进行HE的分层。此项研究数据还突出了他汀类药物在减少肝硬化并发症(包括HE)中的作用。

原始出处:
Tapper EB, Parikh N, et al. A Risk Score to Predict the Development of Hepatic Encephalopathy in a Population-Based Cohort of Patients with Cirrhosis. Hepatology. 2017 Nov 1. doi: 10.1002/hep.29628. 

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1666406, encodeId=08c9166640616, content=<a href='/topic/show?id=55c6849451c' target=_blank style='color:#2F92EE;'>#脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84945, encryptionId=55c6849451c, topicName=脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db0126060584, createdName=showtest, createdTime=Wed May 02 11:06:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258957, encodeId=ef8525895ef2, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sun Nov 05 21:49:38 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426878, encodeId=633a14268e85c, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Nov 04 11:06:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258131, encodeId=40ba2581314b, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Thu Nov 02 21:06:46 CST 2017, time=2017-11-02, status=1, ipAttribution=)]
    2018-05-02 showtest
  2. [GetPortalCommentsPageByObjectIdResponse(id=1666406, encodeId=08c9166640616, content=<a href='/topic/show?id=55c6849451c' target=_blank style='color:#2F92EE;'>#脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84945, encryptionId=55c6849451c, topicName=脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db0126060584, createdName=showtest, createdTime=Wed May 02 11:06:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258957, encodeId=ef8525895ef2, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sun Nov 05 21:49:38 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426878, encodeId=633a14268e85c, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Nov 04 11:06:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258131, encodeId=40ba2581314b, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Thu Nov 02 21:06:46 CST 2017, time=2017-11-02, status=1, ipAttribution=)]
    2017-11-05 thlabcde

    好资料学习了!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1666406, encodeId=08c9166640616, content=<a href='/topic/show?id=55c6849451c' target=_blank style='color:#2F92EE;'>#脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84945, encryptionId=55c6849451c, topicName=脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db0126060584, createdName=showtest, createdTime=Wed May 02 11:06:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258957, encodeId=ef8525895ef2, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sun Nov 05 21:49:38 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426878, encodeId=633a14268e85c, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Nov 04 11:06:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258131, encodeId=40ba2581314b, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Thu Nov 02 21:06:46 CST 2017, time=2017-11-02, status=1, ipAttribution=)]
    2017-11-04 gwc384
  4. [GetPortalCommentsPageByObjectIdResponse(id=1666406, encodeId=08c9166640616, content=<a href='/topic/show?id=55c6849451c' target=_blank style='color:#2F92EE;'>#脑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84945, encryptionId=55c6849451c, topicName=脑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db0126060584, createdName=showtest, createdTime=Wed May 02 11:06:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258957, encodeId=ef8525895ef2, content=好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Sun Nov 05 21:49:38 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426878, encodeId=633a14268e85c, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Nov 04 11:06:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258131, encodeId=40ba2581314b, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Thu Nov 02 21:06:46 CST 2017, time=2017-11-02, status=1, ipAttribution=)]
    2017-11-02 Y—xianghai

    学习了新知识

    0

相关资讯

AASLD中国之声:聚焦多领域,多项成果在会上展示

第68届美国肝病研究学会(AASLD)年会上,贾继东教授及尤红教授团队带来了涵盖慢性乙型肝炎、原发性胆汁性胆管炎、药物性肝损伤、遗传性血色病以及肝纤维化/肝硬化的多项基础和临床研究成果,内容丰富,覆盖面广。快快跟随小编一起看看都有哪些精彩内容!

J Clin Gastroenterol:揭开法国肝硬化患者白蛋白的应用情况

2017年8月,发表在《J Clin Gastroenterol》的一项研究调查了法国肝硬化患者中白蛋白的应用情况。

乙肝治疗三个“不等于”

许多乙肝患者对长期治疗没有足够的心理准备,常常中断治疗。 为此,我总结了乙肝治疗中的3个“不等于”,有针对性地纠正一些误区。

AASLD2017:HVPG可以预测NASH代偿期肝硬化患者的临床疾病进展

应用肝静脉压力梯度(HVPG)值可以独立预测酒精性肝硬化或病毒性肝炎肝硬化患者的临床失代偿风险,然而,其用于非酒精性脂肪性肝炎(NASH)患者的数据有限。在本届AASL年会上,西班牙巴塞罗那大学Bosch等交流的一项研究表明,NASH代偿期肝硬化患者的基线HVPG检测水平及其随着时间的变化,与临床疾病进展的风险独立相关。

Aliment Pharm Therap:他汀常规使用与降低酒精性肝硬化患者死亡率相关

肝硬化是多种病因引起的慢性肝病的终末期。在全球范围内,慢性病毒性肝炎是肝硬化最常见的原因,而第二大常见原因是饮酒过量。证据表明他汀类药物对肝硬化的炎症过程具有改善作用。2017年10月,发表在《Aliment Pharmacol Ther》的一项由丹麦科学家进行的全国病例队列研究,考察了他汀使用与酒精性肝硬化患者死亡率的相关性。

J Gastroen Hepatol:肝硬化胃底静脉曲张破裂出血患者急性肾损伤增加死亡风险

研究发现,胃底静脉曲张破裂出血的肝硬化患者,出现急性肾损伤的现象十分普遍,导致患者6周内的死亡风险增加,急性肾损伤与患者3个月的生存率显著相关

Baidu
map
Baidu
map
Baidu
map